Methylenetetrahydrofolate reductase C677T and overall survival in pediatric acute lymphoblastic leukemia: A systematic review

Leukemia and Lymphoma

Volumn 55, Issue 1, 2014, Pages 67-73

  Ojha, Rohit P ^a   Gurney, James G ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF MEMPHIS   (United States)

Author keywords

Acute lymphoblastic leukemia; Mortality; MTHFR; Pediatric; Survival

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CHILDHOOD CANCER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

ALLELES; CODON; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS;

EID: 84891368024     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.792336     Document Type: Article

References (62)

1. Pul CH, Mullighan CG, Evans WE, et al. Pediatric acute lymphoblastic leukemia: Where are we going and how do we get there? Blood 2012; 120: 1165-1174.
2. Mackall CL. In search of targeted therapies for childhood cancer. Front Oncol 2011; 1: 18.
3. Aplenc R, Lange B. P harmacogenetic determinants of outcome in acute lymphoblastic leukaemia. Br J Haematol 2004; 125: 421-434.
4. Koppen IJ, Hermans FJ, Kaspers G J. Folate related gene polymorphisms and susceptibility to develop childhood acute lymphoblastic leukaemia. Br J Haematol 2010; 148: 3-14.
5. Pereira TV, Rudnicki M, Pereira AC, et al. D o polymorphisms of 5,10-methylenetetrahydrofolate reductase (MTHFR) gene affect the risk of childhood acute lymphoblastic leukemia? Eur J Epidemiol 2006; 21: 885-886.
6. Tong N, Sheng X, Wang M, et al. Methylenetetrahydrofolate reductase gene polymorphisms and acute lymphoblastic leukemia risk: A meta-Analysis based on 28 case-control studies. Leuk Lymphoma 2011; 52: 1949-1960.
7. Wang J, Zhan P, Chen B, et al. MTHFR C677T polymorphisms and childhood acute lymphoblastic leukemia: A meta-Analysis. Leuk Res 2010; 34: 1596-1600.
8. Wang H, Wang J, Zhao L, et al. Methylenetetrahydrofolate reductase polymorphisms and risk of acute lymphoblastic leukemia-evidence from an updated meta-Analysis including 35 studies. BMC Med Genet 2012; 13: 77.
9. Yan J, Yin M, Dreyer ZE, et al. A meta-Analysis of MTHFR C677T and A1298C polymorphisms and risk of acute lymphoblastic leukemia in children. Pediatr Blood Cancer 2012; 58: 513-518.
10. Zintzaras E, Doxani C, Rodopoulou P, et al. Variants of the MTHFR gene and susceptibility to acute lymphoblastic leukemia in children: A synthesis of genetic association studies. Cancer Epidemiol 2012; 36: 169-176.
11. Hider SL, Bruce IN, Th omson W. The pharmacogenetics of methotrexate. Rheumatology (Oxford) 2007; 46: 1520-1524.
12. Kim YI. 5,10-Methylenetetrahydrofolate reductase polymorphisms and pharmacogenetics: A new role of single nucleotide polymorphisms in the folate metabolic pathway in human health and disease. Nutr Rev 2005; 63: 398-407.
13. Seibel N L. Treatment of acute lymphoblastic leukemia in children and adolescents: Peaks and pitfalls. Hematology Am Soc Hematol Educ Program 2008: 374-380.
14. Yang L, Hu X, Xu L. Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: A meta-Analysis. Tumour Biol 2012; 33: 1445-1454.
15. Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, et al. A systematic review and meta-Analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia. Pharmacogenomics J 2012 Oct 23. [Epub ahead of print].
16. Saad ED, Buyse M. Overall survival: Patient outcome, therapeutic objective, clinical trial end point, or public health measure? J. Clin Oncol 2012; 30: 1750-1754.
17. Greenland S, O ' Rourke K. Meta-Analysis. In: Rothman KJ, Greenland S, Lash TL, editors. Modern epidemiology. Philadelphia, PA: Lippincott Williams & Wilkins; 2008. pp. 652-682.
18. Savitz D. Interpreting epidemiologic evidence: Strategies for study design and analysis. Oxford, UK: Oxford University Press; 2003.
19. Pietrzyk JJ, Bik-Multanowski M, Balwierz W, et al. Additional genetic risk factor for death in children with acute lymphoblastic leukemia: A common polymorphism of the MTHFR gene. Pediatr Blood Cancer 2009; 52: 364-368.
20. D'Angelo V, Ramaglia M, Iannotta A, et al. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants. Cancer Chemother Pharmacol 2011; 68: 1339-1346.
21. Tantawy AA, El-Bostany EA, Adly AA, et al. Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis 2010; 21: 28-34.
22. De Deus DM, de Lima EL, Seabra Silva RM, et al. Influence of methylenetetrahydrofolate reductase C677T, A1298C, and G80A polymorphisms on the survival of pediatric patients with acute lymphoblastic leukemia. Leuk Res Treatment 2012; 2012: 292043.
23. Erculj N, Kotnik BF, Debeljak M, et al. Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia. Leuk Lymphoma 2012; 53: 1096-1104.
24. El-Khodary NM, El-Haggar SM, Eid MA, et al. Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia. Med Oncol 2012; 29: 2053-2062.
25. Greenland S. M odel-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in casecontrol studies. Am J. Epidemiol 2004; 160: 301-305.
26. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J. Epidemiol 2005; 162: 199-200.
27. Loomis D, Richardson DB, Elliott L. Poisson regression analysis of ungrouped data. Occup Environ Med 2005; 62: 325-329.
28. Petitti D B. Statistical methods in meta-Analysis. In: P etitti DB, editor. Meta-Analysis, decision analysis, and cost-effectiveness analysis: Methods for quantitative synthesis in medicine. Oxford: Oxford University Press; 2000. pp. 94-118.
29. Thompson SG. Why sources of heterogeneity in meta-Analysis should be investigated. BMJ 1994; 309: 1351-1355.
30. Eysenck HJ. Meta-Analysis and its problems. BMJ 1994; 309: 789-792.
31. Thomas DC, Witte JS. Point: Population stratification: A problem for case-control studies of candidate-gene associations? Cancer Epidemiol Biomarkers Prev 2002; 11: 505-512.
32. Hedges LV, Olkin I. Statistical methods for meta-Analysis. San Diego, CA: Academic Press; 1985.
33. Eissa DS, Ahmed TM. C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: Effect on methotrexaterelated toxicity in adult acute lymphoblastic leukaemia. Blood Coagul Fibrinolysis 2013; 24: 181-188.
34. Chiusolo P, Giammarco S, Bellesi S, et al. The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue. Cancer Chemother Pharmacol 2012; 69: 691-696.
35. De Beaumais TA, Jacqz-Aigrain E. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia. Eur J. Clin Pharmacol 2012; 68: 1233-1242.
36. Hughes A, Giacalone J, Druley T E. Characterizing rare variants in drug metabolism genes in refractory pediatric high-risk pre-B ALL. Blood 2012; 120(Suppl. 1): Abstract 879.
37. Kim H, Kang HJ, Kim HJ, et al. Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: A possible association between survival rate and ITPA polymorphism. PLoS One 2012; 7: E45558.
38. Sepe DM, McWilliams T, Chen J, et al. Germline genetic variation and treatment response on CCG-1891. Pediatr Blood Cancer 2012; 58: 695-700.
39. Tiseo M, Giovannetti E, Tibaldi C, et al. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer 2012; 78: 92-99.
40. Windsor RE, Strauss SJ, Kallis C, et al. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: A pilot study. Cancer 2012; 118: 1856-1867.
41. Salazar J, Altes A, Del Rio E, et al. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia. Pharmacogenomics J. 2012; 12: 379-385.
42. Horinouchi M, Yagi M, Imanishi H, et al. Association of genetic polymorphisms with hepatotoxicity in patients with childhood acute lymphoblastic leukemia or lymphoma. Pediatr Hematol Oncol 2010; 27: 344-354.
43. Goyal RK, Cooper JD. Meta-Analyzing the link between MTHFR C677T genotype and susceptibility to childhood ALL. Pediatr Blood Cancer 2012; 58: 483-484.
44. Karas Kuzelicki N, Milek M, Jazbec J, et al. 5,10- Methylenetetrahydrofolate reductase (MTHFR) low activity genotypes reduce the risk of relapse-related acute lymphoblastic leukemia (ALL). Leuk Res 2009; 33: 1344-1348.
45. Karathanasis NV, Choumerianou DM, Kalmanti M. G ene polymorphisms in childhood ALL. Pediatr Blood Cancer 2009; 52: 318-323.
46. Kim Y I. Role of the MTHFR polymorphisms in cancer risk modification and treatment. Future Oncol 2009; 5: 523-542.
47. Lu Y, Kham SKY, AriffinH, et al. Integrated molecular and pharmacogenetic profi les in prediction of early response to therapy in children with acute lymphoblastic leukemia (ALL): A report from Malaysia-Singapore ALL Study Group. Blood 2009; 114: 1029-1030.
48. Ongaro A, De Mattei M, Della Porta MG, et al. Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: Effects on methotrexate-related toxicity and survival. Haematologica 2009; 94: 1391-1398.
49. Sharma R, Hoskins JM, Rivory LP, et al. Th ymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res 2008; 14: 817-825.
50. Ansari M, St-Onge G, Krajinovic M. [ Pharmacogenomics of acute lymphoblastic leukemia]. Med Sci (Paris) 2007; 23: 961-967.
51. Chiusolo P, Reddiconto G, Farina G, et al. MTHFR polymorphisms ' influence on outcome and toxicity in acute lymphoblastic leukemia patients. Leuk Res 2007; 31: 1669-1674.
52. Gemmati D, Ongaro A, Tognazzo S, et al. Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: Association with toxicity and survival. Haematologica 2007; 92: 478-485.
53. Tower RL, Spector L G. The epidemiology of childhood leukemia with a focus on birth weight and diet. Crit Rev Clin Lab Sci 2007; 44: 203-242.
54. Seidemann K, Book M, Zimmermann M, et al. MTHFR 677 (C-T) polymorphism is not relevant for prognosis or therapy-Associated toxicity in pediatric NHL: Results from 484 patients of multicenter trial NHL-BFM 95. Ann Hematol 2006; 85: 291-300.
55. Davies SM, Borowitz M, Devidas M, et al. Pharmacogenetics of minimal residual disease response in children with acute lymphoblastic leukemia (ALL). Blood 2004; 104(Suppl. 1): Abstract 451.
56. Krajinovic M, Lemieux-Blanchard E, Chiasson S, et al. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2004; 4: 66-72.
57. Olimpieri OM, Schiavon G, Giannetti B, et al. Th rombophilic genetic mutations have no impact in the pathogenesis of thromboembolism in gastro-intestinal cancer patients. Blood 2004; 104(Suppl. 1): Abstract 3518.
58. Bernbeck B, Mauz-Korholz C, Zotz RB, et al. Methylenetetrahydrofolate reductase gene polymorphism and glucocorticoid intake in children with ALL and aseptic osteonecrosis. Klin Padiatr 2003; 215: 327-331.
59. Nagasubramanian R, Innocenti F, Ratain MJ. Pharmacogenetics in cancer treatment. Annu Rev Med 2003; 54: 437-452.
60. Nowak-Gottl U, Wermes C, Junker R, et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999; 93: 1595-1599.
61. Wermes C, Fleischhack G, Junker R, et al. Cerebral venous sinus thrombosis in children with acute lymphoblastic leukemia carrying the MTHFR TT677 genotype and further prothrombotic risk factors. Klin Padiatr 1999; 211: 211-214.
62. Serre D, Paabo S. E vidence for gradients of human genetic diversity within and among continents. Genome Res 2004; 14: 1679-1685.